A small molecule neoantigen immuno-oncology business called Neophore, with headquarters in Cambridge, UK, has secured an unknown sum of money for Series B extension investment.
Investor
- Bristol Myers Squibb (NYSE: BMY)
Use of funds
With the money, the business hopes to advance its pre-clinical research, discover new biology related to the DNA mismatch repair (or “MMR”) pathway in cancer, and produce a candidate medication by 2025.
The CRT Pioneer Fund spun off NeoPhore from PhoreMost Ltd. and the University of Turin.
About NeoPhore
NeoPhore, under the direction of CEO Dr. Matthew Baker, is focused on developing a small molecule medication pipeline that targets new proteins throughout the MMR pathway in order to provide immuno-oncology treatments that will enhance the clinical results of cancer patients. Its MMR inhibitors make solid tumors more immunogenic and neoantigen-expressing, making them very responsive to immunotherapy.
